ResearcherUniversity of California, Los AngelesNo recent work listed

J J Farrell

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5008937873. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2012: 2 papers

Papers 2

EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer… First author DOI 10.1016/j.gie.2011.10.007 ↗
Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Co-author DOI 10.1038/tpj.2011.22 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chandan Guha · 1 shared paper, 2012 · strength 0.04
- Paper Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreati… DOI 10.1038/tpj.2011.22 ↗
Adam Paul Dicker · 1 shared paper, 2012 · strength 0.04
- Paper Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreati… DOI 10.1038/tpj.2011.22 ↗
Hany Elsaleh · 1 shared paper, 2012 · strength 0.04
- Paper Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreati… DOI 10.1038/tpj.2011.22 ↗
Milind M. Javle · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Mark Thornton · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Nader N Hanna · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Marcia Irene Canto · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Joel Randolph Hecht · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Mitchell C. Posner · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Irving Waxman · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Alexander S. Rosemurgy · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
John J. Nemunaitis · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗
Kenneth J. Chang · 1 shared paper, 2012 · strength 0.02
- Paper EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatme… DOI 10.1016/j.gie.2011.10.007 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.